Cargando…

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent oncogenic activities in a variety of human cancers. A large number of EGFR inhibitors have been developed for cancer tr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Zhang, Yuesheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Pharmacology and Experimental Therapeutics 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595022/ https://www.ncbi.nlm.nih.gov/pubmed/37339882 http://dx.doi.org/10.1124/pharmrev.123.000906

Ejemplares similares

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Allosteric regulation of the epidermal growth factor receptor kinase
Publicado: (1986)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Molecular Determinants of Glioblastoma Response to Epidermal Growth Factor Receptor Kinase Inhibitors
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
por: Laux, I, et al.
Publicado: (2006)

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor
por: Högnäsbacka, Antonia, et al.
Publicado: (2022)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

Analysis of the epidermal growth factor receptor/phosphoinositide‐dependent protein kinase‐1 axis in tumor of the external auditory canal in response to epidermal growth factor stimulation
por: Akiyama, Naotaro, et al.
Publicado: (2022)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
por: Dahse, R, et al.
Publicado: (2009)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

BE‐23372M, a Novel and Specific Inhibitor for Epidermal Growth Factor Receptor Kinase
por: Tanaka, Seiichi, et al.
Publicado: (1994)

Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors
por: Li, Dong-Dong, et al.
Publicado: (2020)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
por: Nagano, Tatsuya, et al.
Publicado: (2018)

CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer
por: Huang, Li-Chi, et al.
Publicado: (2018)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
por: Högnäsbacka, Antonia A., et al.
Publicado: (2023)

Epidermal growth factor receptor levels are reduced in mice with targeted disruption of the protein kinase A catalytic subunit
por: Oksvold, Morten P, et al.
Publicado: (2008)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review
por: AlMazmomy, Asim M, et al.
Publicado: (2019)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
por: Shraim, Bara A., et al.
Publicado: (2021)

Orthovanadate-induced vasocontraction is mediated by the activation of Rho-kinase through Src-dependent transactivation of epidermal growth factor receptor
por: Yayama, Katsutoshi, et al.
Publicado: (2014)

Profiling Epidermal Growth Factor Receptor and Heregulin Receptor 3 Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology
por: Ayoub, Mohammed Akli, et al.
Publicado: (2013)

Perinuclear location and recycling of epidermal growth factor receptor kinase: immunofluorescent visualization using antibodies directed to kinase and extracellular domains
Publicado: (1986)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Association of the epidermal growth factor receptor kinase with the detergent-insoluble cytoskeleton of A431 cells
Publicado: (1985)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor
por: Pulit-Penaloza, Joanna A., et al.
Publicado: (2015)

Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells
por: Mantovani, Fernanda B., et al.
Publicado: (2016)

Activated Protein Kinase C (PKC) Is Persistently Trafficked with Epidermal Growth Factor (EGF) Receptor
por: Heckman, Carol A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v41occkq1qjn2stnmloqhe4jne